1. Protein Tyrosine Kinase/RTK
    Autophagy
  2. VEGFR
    Autophagy

Regorafenib (Synonyms: BAY 73-4506)

Cat. No.: HY-10331 Purity: 99.63%
Data Sheet SDS Handling Instructions

Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

For research use only. We do not sell to patients.
Regorafenib Chemical Structure

Regorafenib Chemical Structure

CAS No. : 755037-03-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $72 In-stock
10 mg $65 In-stock
50 mg $90 In-stock
100 mg $120 In-stock
200 mg $190 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Regorafenib:

    Regorafenib purchased from MCE. Usage Cited in: Br J Cancer. 2017 Aug 29.

    The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor–AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

    IC50 & Target

    IC50: 13 nM (VEGFR1), 4.2 nM (VEGFR2), 46 nM (VEGFR3), 22 nM (PDGFRβ), 7 nM (Kit), 1.5 nM (RET), 2.5 nM (Raf-1)

    In Vitro

    Regorafenib potently inhibits VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with an IC50 of 3 nM. In HAoSMCs, regorafenib inhibits PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of 3 nM[1]. Regorafenib causes a concentration-dependent decrease in Hep3B cell growth, having an IC50 of 5 μM. Regorafenib subsequently increases the levels of phospho-c-Jun, a JNK target, but not total c-Jun in Hep3B cells[3].

    In Vivo

    Regorafenib effectively inhibits growth of the Colo-205 xenografts in the dose range of 10-100 mg/kg reaching a TGI of 75% at day 14 at the 10 mg/kg dose. In the MDA-MB-231 model, regorafenib is highly efficacious at a dose as low as 3 mg/kg, resulting in a significant TGI of 81%, which increases to 93% at doses of 10 and 30 mg/kg, where tumor stasis is reached[1].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT01959269 Bayer Colorectal Neoplasm October 31, 2013
    NCT02287025 Bayer Physician Education November 2014 Phase 4
    NCT01298570 UNC Lineberger Comprehensive Cancer Center|Bayer Colorectal Cancer Metastatic February 2011 Phase 2
    NCT01318265 Bayer Pharmacokinetics March 2011 Phase 1
    NCT01003015 Bayer Carcinoma, Hepatocellular September 2009 Phase 2
    NCT00664326 Bayer Carcinoma, Renal Cell April 30, 2008 Phase 2
    NCT01853046 Bayer Neoplasms June 2013 Phase 1
    NCT00934882 Bayer Colorectal Neoplasms August 2009 Phase 1
    NCT01096030 Bayer Neoplasms July 2010 Phase 1
    NCT01322438 Bayer Neoplasms March 2011 Phase 1
    NCT01843400 Bayer Colorectal Neoplasms April 22, 2013
    NCT00960258 Bayer Tumors July 2009 Phase 1
    NCT01339104 Bayer Neoplasms April 2011 Phase 1
    NCT02465502 Bayer Colorectal Neoplasms July 21, 2015 Phase 2
    NCT01933958 Bayer Gastrointestinal Stromal Tumors September 4, 2013
    NCT02168777 Bayer Neoplasms June 2014 Phase 1
    NCT01117623 Bayer Neoplasm February 2007 Phase 1
    NCT01287598 Bayer Neoplasms August 2, 2011 Phase 1
    NCT01002378 Bayer Dietary Fats|Pharmacokinetics October 2009 Phase 1
    NCT01973868 Bayer Neoplasms November 21, 2013 Phase 1
    NCT02398513 Bayer Oncology April 2015 Phase 1
    NCT01774344 Bayer Carcinoma, Hepatocellular May 14, 2013 Phase 3
    NCT02001909 Bayer Neoplasms December 2013 Phase 1
    NCT02106858 Bayer Colorectal Neoplasms June 25, 2014
    NCT01187615 Bayer Small Cell Lung Carcinoma August 2010 Phase 1
    NCT02656524 Bayer Colorectal Neoplasms May 16, 2016
    NCT01646593 Bayer Gastrointestinal Stromal Tumors
    NCT02347852 Bayer Colorectal Neoplasms January 2015
    NCT01689376 Bayer Gastrointestinal Stromal Tumors
    NCT02085148 Bayer Pediatric Oncology April 11, 2014 Phase 1
    NCT02042144 Bayer Neoplasms April 8, 2014
    NCT01538680 Bayer Colorectal Neoplasms
    NCT01584830 Bayer Colorectal Neoplasms April 2012 Phase 3
    NCT02106845 Bayer Neoplasms April 22, 2014 Phase 1
    NCT01939223 Bayer Colorectal Neoplasms December 2013 Phase 3
    NCT01289821 Bayer Colorectal Neoplasms February 2011 Phase 2
    NCT01271712 Bayer Gastrointestinal Stromal Tumors January 2011 Phase 3
    NCT01103323 Bayer Metastatic Colorectal Cancer April 2010 Phase 3
    NCT02222207 Bayer Macular Degeneration October 2014 Phase 2
    NCT01959269 Bayer Colorectal Neoplasm October 31, 2013
    NCT02287025 Bayer Physician Education November 2014 Phase 4
    NCT01298570 UNC Lineberger Comprehensive Cancer Center|Bayer Colorectal Cancer Metastatic February 2011 Phase 2
    NCT01318265 Bayer Pharmacokinetics March 2011 Phase 1
    NCT01003015 Bayer Carcinoma, Hepatocellular September 2009 Phase 2
    NCT00664326 Bayer Carcinoma, Renal Cell April 30, 2008 Phase 2
    NCT01853046 Bayer Neoplasms June 2013 Phase 1
    NCT00934882 Bayer Colorectal Neoplasms August 2009 Phase 1
    NCT01096030 Bayer Neoplasms July 2010 Phase 1
    NCT01322438 Bayer Neoplasms March 2011 Phase 1
    NCT01843400 Bayer Colorectal Neoplasms April 22, 2013
    NCT00960258 Bayer Tumors July 2009 Phase 1
    NCT01339104 Bayer Neoplasms April 2011 Phase 1
    NCT02465502 Bayer Colorectal Neoplasms July 21, 2015 Phase 2
    NCT01933958 Bayer Gastrointestinal Stromal Tumors September 4, 2013
    NCT02168777 Bayer Neoplasms June 2014 Phase 1
    NCT01117623 Bayer Neoplasm February 2007 Phase 1
    NCT01287598 Bayer Neoplasms August 2, 2011 Phase 1
    NCT01002378 Bayer Dietary Fats|Pharmacokinetics October 2009 Phase 1
    NCT01973868 Bayer Neoplasms November 21, 2013 Phase 1
    NCT02398513 Bayer Oncology April 2015 Phase 1
    NCT01774344 Bayer Carcinoma, Hepatocellular May 14, 2013 Phase 3
    NCT02001909 Bayer Neoplasms December 2013 Phase 1
    NCT02106858 Bayer Colorectal Neoplasms June 25, 2014
    NCT01187615 Bayer Small Cell Lung Carcinoma August 2010 Phase 1
    NCT02656524 Bayer Colorectal Neoplasms May 16, 2016
    NCT01646593 Bayer Gastrointestinal Stromal Tumors
    NCT02347852 Bayer Colorectal Neoplasms January 2015
    NCT01689376 Bayer Gastrointestinal Stromal Tumors
    NCT02085148 Bayer Pediatric Oncology April 11, 2014 Phase 1
    NCT02042144 Bayer Neoplasms April 8, 2014
    NCT01538680 Bayer Colorectal Neoplasms
    NCT01584830 Bayer Colorectal Neoplasms April 2012 Phase 3
    NCT02106845 Bayer Neoplasms April 22, 2014 Phase 1
    NCT01939223 Bayer Colorectal Neoplasms December 2013 Phase 3
    NCT01289821 Bayer Colorectal Neoplasms February 2011 Phase 2
    NCT01271712 Bayer Gastrointestinal Stromal Tumors January 2011 Phase 3
    NCT01103323 Bayer Metastatic Colorectal Cancer April 2010 Phase 3
    NCT02222207 Bayer Macular Degeneration October 2014 Phase 2
    NCT02439723 AHS Cancer Control Alberta|Cross Cancer Institute Metastatic Solid Malignancies|Locally Advanced Solid Malignancies March 2016 Phase 1
    NCT02175095 Asan Medical Center Colorectal Cancer July 2014
    NCT01929616 Jules Bordet Institute Advanced Chemorefractory Colorectal Adenocarcinoma August 2013 Phase 2
    NCT01949194 Gerald Batist|Bayer|Quebec Clinical Research Organization in Cancer|Jewish General Hospital Metastatic Colorectal Cancer September 2013 Phase 2
    NCT02307500 Istituto Clinico Humanitas Pancreas Cancer|Ovarian Cancer|Melanoma|Sarcoma December 2014 Phase 2
    NCT02651415 British Columbia Cancer Agency|Bayer Metastatic Colorectal Cancer August 2016 Phase 2
    NCT03042689 Massachusetts General Hospital|Bayer Acute Myeloid Leukemia January 2017 Phase 1
    NCT01068769 Suzanne George, MD|Brigham and Women's Hospital|Massachusetts General Hospital|Fox Chase Cancer Center|Oregon Health and Science University|Bayer|Dana-Farber Cancer Institute Gastrointestinal Stromal Tumor February 2010 Phase 2
    NCT02115542 H. Lee Moffitt Cancer Center and Research Institute|Bayer Cancer of the Bile Duct April 10, 2014 Phase 2
    NCT02095054 M.D. Anderson Cancer Center Advanced Cancers March 19, 2014 Phase 1
    NCT02466802 Virginia Commonwealth University|Bayer Solid Tumor July 1, 2015 Phase 1
    NCT02402036 Georgetown University|Bayer Colon Cancer February 2015 Phase 2
    NCT02657551 Dana-Farber Cancer Institute|Bayer Thyroid Cancer January 2016 Phase 2
    NCT02459119 University of Alabama at Birmingham|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) May 2015 Phase 2
    NCT01853319 Bayer Colorectal Neoplasms July 24, 2013 Phase 3
    NCT02736305 National Cancer Centre, Singapore Ovarian Neoplasms February 2016 Phase 2
    NCT02581059 Rodwige J. Desnoyers|Bayer|Hoosier Cancer Research Network Colorectal Cancer|Palliative Medicine|Supportive Care April 2016 Phase 2
    NCT02116894 Herbert Hurwitz, MD|Pfizer|Duke University Colorectal Cancer August 2014 Phase 1
    NCT02053376 University of Pittsburgh|Bayer Metastatic Biliary Tract Carcinoma January 2014 Phase 2
    NCT02606097 Chang Gung Memorial Hospital Gastrointestinal Stromal Tumour (GIST) April 2014 Phase 2
    NCT02466009 University of Rochester|Bayer Metastatic Colorectal Cancer March 2015 Phase 2
    NCT02425683 US Oncology Research|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma Colorectal Neoplasms|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum March 2015 Phase 2
    NCT02023333 Memorial Sloan Kettering Cancer Center|Bayer|State University of New York - Downstate Medical Center|Queens Cancer Center of Queens Hospital Metastatic Colorectal Adenocarcinoma December 2013 Phase 2
    NCT02310477 Centre Oscar Lambret|Bayer Metastatic Colorectal Cancer February 2014
    NCT01996969 Seoul National University Hospital|Bayer Metastatic Colorectal Cancer October 2013
    NCT02080260 Stuart Salmon|Bayer|Carolinas Healthcare System Pancreatic Cancer June 2014 Phase 2
    NCT03010722 Royal Marsden NHS Foundation Trust|Bayer Metastatic Colorectal Cancer January 2015 Phase 2
    NCT01900743 Centre Oscar Lambret|Bayer Sarcoma June 2013 Phase 2
    NCT02638766 Grupo Espanol de Investigacion en Sarcomas|Bayer Gastrointestinal Stromal Tumors November 2015 Phase 2
    NCT02699073 Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) Metastatic Colorectal Cancer February 2016 Phase 2
    NCT02048722 Northwestern University|Bayer|National Cancer Institute (NCI) Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma March 2014 Phase 2
    NCT02889328 Asan Medical Center Gastrointestinal Stromal Tumors (GISTs) September 2016 Phase 2
    NCT02195011 SCRI Development Innovations, LLC|Sirtex Medical Colorectal Neoplasms July 2014 Phase 2
    NCT02287727 Roswell Park Cancer Institute|National Cancer Institute (NCI) Rectal Adenocarcinoma|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer March 2015 Phase 2
    NCT02098538 Memorial Sloan Kettering Cancer Center|Bayer Adenoid Cystic Carcinoma March 2014 Phase 2
    NCT02926222 Istituto Oncologico Veneto IRCCS|BAYER S.p.A. - Italia Glioblastoma Multiforme November 2015 Phase 2
    NCT02501551 Yonsei University Melanoma February 2015 Phase 2
    NCT02664077 NSABP Foundation Inc|Bayer Stage III (IIIB or IIIC) Colon Cancer June 2016 Phase 3
    NCT01875380 Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer Colorectal Neoplasms|Metastatic Disease June 2013 Phase 2
    NCT02164240 Dana-Farber Cancer Institute|Bayer|Pfizer Gastrointestinal Stromal Tumor July 2014 Phase 1
    NCT02162914 Erasme University Hospital Cholangiocarcinoma March 2014 Phase 2
    NCT02241720 University of Utah Upper GI Cancer May 2014 Phase 2
    NCT02259725 University of Southern California|National Cancer Institute (NCI) Gastrinoma|Glucagonoma|Insulinoma|Metastatic Gastrointestinal Carcinoid Tumor|Pancreatic Polypeptide Tumor|Pulmonary Carcinoid Tumor|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma August 16, 2016 Phase 2
    NCT02199223 University of Utah KRAS and NRAS Wild-type Colorectal Cancer June 2014 Phase 1
    NCT02175654 Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer Colorectal Neoplasms|Metastatic Disease June 2014 Phase 2
    NCT02406170 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Esophageal Neoplasms|Stomach Neoplasms|Neoplasm Metastasis April 2015 Phase 1|Phase 2
    NCT01913639 Memorial Sloan Kettering Cancer Center|Bayer Esophageal Cancer|Gastric Cancer July 2013 Phase 2
    NCT02096354 EpicentRx, Inc. Colorectal Neoplasms May 2014 Phase 2
    NCT02383433 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Metastatic Pancreatic Adenocarcinoma June 14, 2016 Phase 2
    NCT02619435 National Cancer Institute, Naples Advanced Colorectal Cancer November 2015 Phase 2
    NCT02800330 Erasmus Medical Center Colorectal Neoplasms|Gastrointestinal Stromal Tumors May 2016 Phase 4
    NCT02910843 Swiss Group for Clinical Cancer Research Rectal Cancer February 22, 2017 Phase 1
    NCT02234180 Academic and Community Cancer Research United|National Cancer Institute (NCI) Adenocarcinoma of the Gastroesophageal Junction|Stage IIB Esophageal Adenocarcinoma|Stage IIIA Esophageal Adenocarcinoma|Stage IIIB Esophageal Adenocarcinoma|Stage IIIC Esophageal Adenocarcinoma September 2014 Phase 2
    NCT02773524 Australasian Gastro-Intestinal Trials Group|Canadian Cancer Trials Group Gastro-Oesophageal Cancer June 2016 Phase 3
    NCT02278783 University of Utah|Bayer Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer March 2015 Phase 2
    NCT02389244 UNICANCER Ewing Sarcomas|Chondrosarcomas|Osteosarcomas|Chondroma September 2014 Phase 2
    NCT01786538 Asan Medical Center Metastatic Colorectal Cancer June 2013 Phase 3
    NCT02584465 ARCAGY/ GINECO GROUP|Bayer Ovarian Carcinoma September 2015 Phase 2
    NCT02835924 Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Bayer Metastatic Colorectal Cancer July 2016 Phase 2
    NCT03081494 Novartis Pharmaceuticals|Novartis Metastatic Colorectal Cancer June 9, 2017 Phase 1
    NCT03099486 Fox Chase Cancer Center Colorectal Cancer June 30, 2017 Phase 2
    NCT02386397 Institut du Cancer de Montpellier - Val d'Aurelle Digestive Cancer September 2014 Phase 1|Phase 2
    NCT02788006 Federation Francophone de Cancerologie Digestive Colorectal Adenocarcinoma January 2016 Phase 2
    NCT02368886 Academic and Community Cancer Research United|National Cancer Institute (NCI) Colon Adenocarcinoma|Rectal Adenocarcinoma|Stage III Colorectal Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer March 2015 Phase 2
    NCT01896856 Sidney Kimmel Comprehensive Cancer Center Previously Treated Metastatic Colorectal Cancer September 2013 Phase 1|Phase 2
    NCT02316340 The University of Texas Health Science Center at San Antonio Colorectal Cancer February 2015 Phase 2
    NCT02288078 Clinical Research Support Center Kyush Rectal Cancer October 2014 Phase 2
    NCT02048371 Sarcoma Alliance for Research through Collaboration Liposarcoma|Osteogenic Sarcoma|Ewing/Ewing-like Sarcoma July 2014 Phase 2
    NCT02788279 Hoffmann-La Roche Colorectal Cancer July 5, 2016 Phase 3
    NCT01189903 National University Hospital, Singapore Asian Colorectal Cancer Patients January 2011 Phase 2|Phase 3
    NCT02119676 Incyte Corporation Metastatic Colorectal Cancer March 2014 Phase 2
    NCT02365441 Australasian Gastro-Intestinal Trials Group|European Organisation for Research and Treatment of Cancer - EORTC|Scandinavian Sarcoma Group Gastrointestinal Stromal Tumour February 2015 Phase 2
    NCT02940223 M.D. Anderson Cancer Center|Bayer Malignant Neoplasms of Independent (Primary) Multiple Sites March 16, 2017 Phase 2
    NCT03215264 Abramson Cancer Center of the University of Pennsylvania Colorectal Cancer July 10, 2017 Phase 1|Phase 2
    NCT02795156 SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma September 28, 2016 Phase 2
    NCT02955940 Incyte Corporation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell November 2016 Phase 2
    NCT02024607 Boston Biomedical, Inc Advanced Gastrointestinal Cancer January 2014 Phase 1|Phase 2
    NCT02587650 Adil Daud|University of California, San Francisco Melanoma May 2016 Phase 2
    NCT02925234 The Netherlands Cancer Institute|Amgen|AstraZeneca|Bayer|Bristol-Myers Squibb|Novartis|Roche Pharma AG Cancer|Tumors|Neoplasm|Neoplasia August 2016 Phase 2
    NCT02693535 American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors March 2016 Phase 2
    NCT02934529 Ludwig-Maximilians - University of Munich Metastatic Colorectal Cancer March 2015 Phase 3
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 2.0712 mL 10.3558 mL 20.7117 mL
    5 mM 0.4142 mL 2.0712 mL 4.1423 mL
    10 mM 0.2071 mL 1.0356 mL 2.0712 mL
    Kinase Assay
    [1]

    Initial in vitro kinase inhibition profiling is performed at Millipore Corporation at a fixed 1 μM compound concentration under Millipore standard conditions [10 μM adenosine-5′-triphosphate (ATP) concentration]. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases,e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    Regorafenib is diluted in complete growth media to between 10 μM and 5 nM final concentrations.

    For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37°C. The next day, vehicle or regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hr. Cell proliferation is quantified using CellTitre-GloTM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Regorafenib is formulated as a solution in either PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua).

    Female athymic NCr nu/nu mice, kept in accordance with Federal guidelines, are subcutaneously inoculated with 5×106 Colo-205 or MDA-MB-231 cells or implanted with 1 mm3 786-O tumor fragments. When tumors reach a volume of 100 mm3, regorafenib or vehicle control is administered orally qd×21 in the 786-O model, and qd×9 in the Colo-205 and MDA-MB-231 models, respectively, at doses of 100, 30, 10, and 3 mg/kg. Paclitaxel is administered intravenously at 10 mg/kg in ethanol/Cremophor EL®/saline (12.5%/12.5%/75%) every 2 days×5. Tumor size (volume) is estimated twice weekly (l×w2)/2, and the percentage of tumor growth inhibition (TGI) is obtained from terminal tumor weights (1-T/C×100). Mice are weighed every other day starting from the first day of treatment. The general health status of the mice is monitored daily. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    482.82

    Formula

    C₂₁H₁₅ClF₄N₄O₃

    CAS No.

    755037-03-7

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 260 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.63%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Regorafenib
    Cat. No.:
    HY-10331
    Quantity: